Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
In the latest session, ImmunityBio Inc (NASDAQ: IBRX) closed at $2.02 up 2.02% from its previous closing price of $1.98. In other words, the price has increased by $2.02 from its previous closing price. On the day, 10.25 million shares were traded. IBRX stock price reached its highest trading level at $2.07 during the session, while it also had its lowest trading level at $1.98.
Ratios:
For a deeper understanding of ImmunityBio Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.65 and its Current Ratio is at 5.77.
On March 06, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $8.
On January 10, 2025, BTIG Research started tracking the stock assigning a Buy rating and target price of $6.BTIG Research initiated its Buy rating on January 10, 2025, with a $6 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IBRX now has a Market Capitalization of 1989629696 and an Enterprise Value of 2594014720. For the stock, the TTM Price-to-Sale (P/S) ratio is 24.10. Its current Enterprise Value per Revenue stands at 31.422 whereas that against EBITDA is -10.59.
Stock Price History:
The Beta on a monthly basis for IBRX is -0.10, which has changed by -0.26811594 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, IBRX has reached a high of $4.27, while it has fallen to a 52-week low of $1.83. The 50-Day Moving Average of the stock is -7.97%, while the 200-Day Moving Average is calculated to be -19.94%.
Shares Statistics:
For the past three months, IBRX has traded an average of 11.10M shares per day and 13896410 over the past ten days. A total of 984.97M shares are outstanding, with a floating share count of 330.78M. Insiders hold about 66.42% of the company’s shares, while institutions hold 14.62% stake in the company. Shares short for IBRX as of 1765756800 were 109024436 with a Short Ratio of 9.83, compared to 1763078400 on 81064526. Therefore, it implies a Short% of Shares Outstanding of 109024436 and a Short% of Float of 32.950002.
Earnings Estimates
The dynamic stock of ImmunityBio Inc (IBRX) is currently being evaluated by a team of 3.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.07 and low estimates of -$0.07.
Analysts are recommending an EPS of between -$0.35 and -$0.47 for the fiscal current year, implying an average EPS of -$0.4. EPS for the following year is -$0.26, with 3.0 analysts recommending between -$0.24 and -$0.28.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $35.99M this quarter.It ranges from a high estimate of $40.83M to a low estimate of $34M. As of. The current estimate, ImmunityBio Inc’s year-ago sales were $7.55MFor the next quarter, 5 analysts are estimating revenue of $39.25M. There is a high estimate of $43.5M for the next quarter, whereas the lowest estimate is $35M.
A total of 5 analysts have provided revenue estimates for IBRX’s current fiscal year. The highest revenue estimate was $115.5M, while the lowest revenue estimate was $109M, resulting in an average revenue estimate of $110.96M. In the same quarter a year ago, actual revenue was $14.74MBased on 5 analysts’ estimates, the company’s revenue will be $214.08M in the next fiscal year. The high estimate is $248.7M and the low estimate is $155.83M.
